SCHEMBL5534902

SCHEMBL5534902

Cc1nc(-c2ccc(Cl)cc2)oc1C

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 7/20 0.59
ALDH1A1 P00352 5/20 0.55
LMNA P02545 3/20 0.55
TARBP2 Q15633 1/20 0.53
HPGD P15428 4/20 0.47
SMN1; SMN2 Q16637 4/20 0.47
NFKB1 P19838 1/20 0.47
NFKB2 Q00653 1/20 0.47
RELA Q04206 1/20 0.47
IKBKB O14920 1/20 0.47
NR1H4 Q96RI1 1/20 0.47
HSD17B10 Q99714 3/20 0.46
NPC1 O15118 4/20 0.45
RAB9A P51151 4/20 0.45
CYP1A2 P05177 2/20 0.45
CYP2C19 P33261 2/20 0.45
NPSR1 Q6W5P4 2/20 0.45
ALOX12 P18054 2/20 0.45
MAOB P27338 1/20 0.45
XBP1 P17861 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2706143 0.83 NPC1 (0.52) KDM4EALDH1A1LMNATARBP2HPGD
SCHEMBL5534898 0.81 TARBP2 (0.50) KDM4EALDH1A1LMNATARBP2HPGD
SCHEMBL5546864 0.81 KDM4E (0.53) KDM4EALDH1A1LMNATARBP2HPGD
SCHEMBL9862893 0.80 NPC1 (0.51) KDM4ESMN1; SMN2NFKB1NFKB2RELA
SCHEMBL1557048 0.80 TARBP2 (0.53) KDM4EALDH1A1LMNATARBP2HPGD
SCHEMBL24125061 0.80 RAB9A (0.52) KDM4EALDH1A1HPGDSMN1; SMN2NFKB1
SCHEMBL14431592 0.80 GAA (0.54) KDM4EALDH1A1TARBP2HPGDSMN1; SMN2
SCHEMBL5543997 0.80 NPC1 (0.52) KDM4EALDH1A1HPGDSMN1; SMN2HSD17B10
SCHEMBL436384 0.79 GAA (0.57) KDM4EALDH1A1TARBP2HPGDSMN1; SMN2
SCHEMBL13179907 0.78 HSD17B10 (0.58) KDM4EALDH1A1LMNATARBP2HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20200345700-A1 LSD1 INHIBITOR AND PREPARATION METHOD AND APPLICATION THEREOF MEDSHINE DISCOVERY INC. (CN) 2020-11-05 US disclosed
US-20150191420-A1 ANTIBACTERIAL AGENTS TAXIS PHARMACEUTICALS, INC. 2015-07-09 US disclosed
US-8865736-B2 Antibacterial agents Biota Scientific Pty Ltd (AU) 2014-10-21 US disclosed
US-20130072520-A2 ANTIBACTERIAL AGENTS BIOTA SCIENTIFIC MANAGEMENT PTY LTD (AU) 2013-03-21 US disclosed
EP-2570418-A2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2013-03-20 EP disclosed
EP-1555267-B1 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES OTSUKA PHARMA CO LTD (JP) 2013-01-16 EP disclosed
US-20120122918-A1 ANTIBACTERIAL AGENTS BIOTA SCIENTIFIC MANAGEMENT PTY LTD (AU) 2012-05-17 US disclosed
US-8088791-B2 Antibacterial agents Biots Scientific Management Pty Ltd (AU) 2012-01-03 US disclosed
US-7902367-B2 Cyclic amino benzoic acid derivative KYORIN PHARMACEUTICAL CO., LTD. (JP) 2011-03-08 US disclosed
US-7902367-B2 Cyclic amino benzoic acid derivative KYORIN PHARMACEUTICAL CO., LTD. (JP) 2011-03-08 US disclosed
US-20100173933-A1 ANTIBACTERIAL AGENTS PROLYSIS LTD (GB) 2010-07-08 US disclosed
US-20070249580-A1 Novel Cyclic Amino Benzoic Acid Derivative KYORIN PHARMACEUTICAL CO., LTD. (JP) 2007-10-25 US disclosed
US-20070249580-A1 Novel Cyclic Amino Benzoic Acid Derivative KYORIN PHARMACEUTICAL CO., LTD. (JP) 2007-10-25 US disclosed
US-7262212-B2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2007-08-28 US disclosed
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2006-05-04 US disclosed
EP-1555267-A1 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2005-07-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120122918-A1 ANTIBACTERIAL AGENTS ALK, ROS1, ARG1 KDM4E 819/4885ALDH1A1 787/4885LMNA 3250/4885
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles NR2C2, NR4A3, NR4A2 KDM4E 4854/4885ALDH1A1 355/4885LMNA 4152/4885
US-20130072520-A2 ANTIBACTERIAL AGENTS ALK, ROS1, NOX1 KDM4E 2407/4885ALDH1A1 800/4885LMNA 1817/4885
US-20150191420-A1 ANTIBACTERIAL AGENTS ALK, ARG1, ROS1 KDM4E 1251/4885ALDH1A1 740/4885LMNA 2877/4885
US-20100173933-A1 ANTIBACTERIAL AGENTS ALK, ROS1, NOX1 KDM4E 2407/4885ALDH1A1 800/4885LMNA 1817/4885
US-20200345700-A1 LSD1 INHIBITOR AND PREPARATION METHOD AND APPLICATION THEREOF KDM1B, KDM1A, KDM2A KDM4E 17/4885ALDH1A1 290/4885LMNA 1018/4885
US-20070249580-A1 Novel Cyclic Amino Benzoic Acid Derivative PPARA, PPARG, PPARD KDM4E 1797/4885ALDH1A1 616/4885LMNA 1906/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.